Eagle Pharma (EGRX) is an integrated pharmaceutical company that works with collaborators to help patients address unmet needs. The company is capable of taking a drug through pre-clinical research through regulatory approval and launching the product into the market place. Eagle is also capable of manufacturing, marketing and commercializing the product post-launch. The company’s niche is in providing proprietary research for rare diseases of the central nervous system or metabolic critical care therapeutic areas and oncology.
Each has proven track record with commercial launches of Ryanodex (muscle spasms), Belrapzo (B-cell non-Hodgkin lymphoma) and Bendeka (chronic lymphocytic leukemia). Eagle markets Ryanodex and Belrapzo, while Teva (TEVA) markets Bendeka. SymBio Pharmaceuticals Limited, markets Treakisym, a RTD product, inJapan. In Q1 2020 Eagle received FDA approval of Pemfexy (malignant pleural mesothelioma), expanding the company’s oncology business.
EGRX recently won FDA approval for generic vasopressin. Vasostrict is Endo’s (ENDP) best-selling product and appealed a patent decision for the drug last summer. Endo appealed the patent decision, yet Eagle still launched on appeal. The move could end up bankrupting Eagle. Are creditors aware of this? Read more: